T1	Outcomes 85 128	exudative age-related macular degeneration.
T2	Outcomes 977 1005	best-corrected visual acuity
T3	Outcomes 1095 1137	number of ranibizumab injections required.
T4	Outcomes 1156 1205	6-month change in central macular thickness (CMT)
T5	Outcomes 1449 1467	no adverse effects
T6	Outcomes 1540 1563	the efficacy and safety
T7	Outcomes 1781 1793	reducing CMT
